Mrc2 Antibody (Quark Patent Anti-Endo180) [DyLight 650]

• Reactivity: Hu
• Applications: ELISA, Flow, Func
• Clone: Quark Patent Anti-Endo180
• Clonality: Monoclonal
• Host: Human
• Conjugate: DyLight 650

Mrc2 Antibody (Quark Patent Anti-Endo180) [DyLight 650] Summary

• Additional Information: Recombinant Monoclonal Antibody
• Immunogen: MRC2 / CD280
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Human
• Gene: MRC2
• Purity: Protein A purified

Applications/Dilutions

• Dilutions:
  • ELISA
  • Flow Cytometry
  • Functional
• Application Notes: Optimal dilution of this antibody should be experimentally determined.

Packaging, Storage & Formulations

• Storage: Store at 4C in the dark.
• Buffer: 50mM Sodium Borate
• Preservative: 0.05% Sodium Azide
• Purity: Protein A purified

Notes

DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.

Alternate Names for Mrc2 Antibody (Quark Patent Anti-Endo180) [DyLight 650]

• CD280 antigen
• CD280
• CD280C-type mannose receptor 2
• CLEC13E
• CLEC13EUPAR-associated protein
• Endo180
• ENDO180C-type lectin domain family 13 member E
• Endocytic receptor 180
• KIAA0709FLJ35911
• Macrophage mannose receptor 2
• mannose receptor, C type 2
• Mrc2
• uPARAP
• UPARAPendocytic receptor (macrophage mannose receptor family)
• urokinase plasminogen activator receptor-associated protein
• Urokinase receptor-associated protein
• Urokinase-type plasminogen activator receptor-associated protein

Background

MRC2, also known as C-type mannose receptor 2, is a 1,479 amino acid protein that is 167 kDa, plays a role in extracellular matrix remodeling by mediating the internalization and lysosomal degradation of collagen ligands, may be involved in plasminogen activation system controlling the extracellular level of PLAUR/PLAU, and thus may regulate protease activity at the cell surface, and may play a role in the tumorigenesis and metastasis of several malignancies including breast cancer, gliomas and metastatic bone disease. Disease research is currently being studied with relations to MRC2 and breast cancer, aortic aneurysm, prostate cancer, progression of osteoarthritis, prostatitis,s, schizophrenia, tuberculosis, immunodeficiency, and hepatitis. Interactions with this protein have shown to involve NDEL1, IL10, TGFB1, TGFB2, TGFB3, and UBC in antigen processing-cross presentation, cross-presentation of soluble exogenous antigens (endosomes), adaptive immune system, class I MHC mediated antigen processing & presentation, immune system, phagosome, and tuberculosis pathways.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: MRC2